Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia

Published:2023-07 Issue: Volume: Page:
ISSN:2531-1379
Container-title:Hematology, Transfusion and Cell Therapy
language:en
Short-container-title:Hematology, Transfusion and Cell Therapy

Author:

Braga Arthur Gomes Oliveira^ORCID,Barbosa Pagnano Katia Borgia^ORCID,Campioni Marina Dal'Bó Pelegrini^ORCID,Lopes Ana Beatriz Pascoal^ORCID,Duarte Gislaine Oliveira,Metze Konradin^ORCID,Lorand-Metze Irene^ORCID

Funder

National Research Council

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Publisher

Elsevier BV

Subject

Hematology,Immunology and Allergy

Reference23 articles.

1. Ross D.M., Branford S., Seymour J.F., Schwarer A.P., Arthur C., Yeung D.T. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease : results from the TWISTER study, 122 (2013) 1–4. https://doi.org/10.1182/blood-2013-02-483750.

2. FINAL analysis of a PAN European STOP tyrosine kinase inhibitor trial in chronic myeloid leukemia : the EURO-SKI study;Mahon;Blood,2021

3. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase;Mahon;Ann Intern Med,2018

4. Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response;Pagnano;Am J Hematol,2020

5. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study;Shah;Leuk Lymphoma,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study;Frontiers in Oncology;2024-05-08